These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34992891)

  • 1. Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis: A Neuromuscular Surprise.
    Ali H; Pamarthy R; Ahsan N; WashmaAwan ; Sarfraz S
    Case Rep Neurol Med; 2021; 2021():1326442. PubMed ID: 34992891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
    Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
    Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MuSK Myasthenia Gravis Presenting with Bilateral Vocal Cord Abduction Paresis: A Case Report and Literature Review.
    Santilli A; Stitt D
    Neurologist; 2021 Sep; 26(5):175-177. PubMed ID: 34491934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
    Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
    Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis.
    Reddel SW; Morsch M; Phillips WD
    Curr Opin Neurol; 2014 Oct; 27(5):558-65. PubMed ID: 25159928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mouse passive-transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure.
    Ghazanfari N; Trajanovska S; Morsch M; Liang SX; Reddel SW; Phillips WD
    Ann N Y Acad Sci; 2018 Jan; 1412(1):54-61. PubMed ID: 29125188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-AChR, MuSK, and LRP4 antibodies coexistence: A rare and distinct subtype of myasthenia gravis from Indian subcontinent.
    Bokoliya SC; Kumar VP; Nashi S; Polavarapu K; Nalini A; Patil SA
    Clin Chim Acta; 2018 Nov; 486():34-35. PubMed ID: 30006288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
    Vincent A; Leite MI
    Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.
    Pevzner A; Schoser B; Peters K; Cosma NC; Karakatsani A; Schalke B; Melms A; Kröger S
    J Neurol; 2012 Mar; 259(3):427-35. PubMed ID: 21814823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.
    Koneczny I; Cossins J; Vincent A
    J Anat; 2014 Jan; 224(1):29-35. PubMed ID: 23458718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment.
    Cao M; Koneczny I; Vincent A
    Front Mol Neurosci; 2020; 13():159. PubMed ID: 32982689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.
    Hurst RL; Gooch CL
    Curr Neurol Neurosci Rep; 2016 Jul; 16(7):61. PubMed ID: 27170368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.
    Phillips WD; Vincent A
    F1000Res; 2016; 5():. PubMed ID: 27408701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seropositive Muscle-Specific Tyrosine Kinase Myasthenia Gravis Presenting as a Late-Onset Isolated Sixth Nerve Palsy: A Case Report and a Brief Review of Subtypes of Myasthenia Gravis.
    Park G; Kesserwani H
    Cureus; 2021 Nov; 13(11):e19701. PubMed ID: 34934570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.
    Phillips WD; Christadoss P; Losen M; Punga AR; Shigemoto K; Verschuuren J; Vincent A
    Exp Neurol; 2015 Aug; 270():29-40. PubMed ID: 25542979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.
    Rivner MH; Pasnoor M; Dimachkie MM; Barohn RJ; Mei L
    Neurol Clin; 2018 May; 36(2):293-310. PubMed ID: 29655451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myasthenia gravis.
    Pourmand R
    Dis Mon; 1997 Feb; 43(2):65-109. PubMed ID: 9118787
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.